{"gene":"TSHR","run_date":"2026-04-28T21:43:00","timeline":{"discoveries":[{"year":2011,"finding":"Crystal structure of TSHR extracellular domain (residues 22-260) bound to blocking-type human monoclonal autoantibody K1-70 solved at 1.9 Å resolution, revealing that K1-70 binds the concave surface of the leucine-rich repeat domain (LRD) in approximately the opposite orientation (~155° rotation) to stimulating autoantibody M22, and more N-terminally on the TSHR concave surface; mutagenesis of interface residues confirmed functional relevance of observed contacts.","method":"X-ray crystallography at 1.9 Å + site-directed mutagenesis","journal":"Journal of molecular endocrinology","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with mutagenesis validation, single rigorous paper with multiple orthogonal methods","pmids":["21247981"],"is_preprint":false},{"year":2015,"finding":"TSHR signaling stimulates proliferation of orbital fibroblasts in thyroid eye disease via the PI3K/Akt pathway and through induction of miR-146a and miR-155, which reduce expression of anti-proliferative targets ZNRF3 and PTEN; TSHR-specific siRNA knockdown abolished TSH-induced proliferation.","method":"siRNA knockdown, BrdU proliferation assay, Western blot, qPCR, PI3K inhibitor (LY294002)","journal":"Investigative ophthalmology & visual science","confidence":"Medium","confidence_rationale":"Tier 2 — clean KD with defined cellular phenotype and multiple pathway inhibitors, single lab","pmids":["31622470"],"is_preprint":false},{"year":2017,"finding":"GLIS3 transcription factor acts downstream of TSH/TSHR signaling and is required for TSH/TSHR-mediated thyroid follicular cell proliferation and thyroid hormone biosynthesis; GLIS3 deficiency blocks TSH-mediated activation of the mTORC1/RPS6 pathway and directly regulates iodide transporter genes NIS and PDS.","method":"ChIP-Seq, promoter analysis, conditional knockout mouse model, signaling pathway analysis","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including ChIP-Seq, mouse KO model with defined phenotype, and pathway dissection","pmids":["29083325"],"is_preprint":false},{"year":2010,"finding":"Tissue-specific knockout of TSHR in white adipose tissue demonstrated that adipocyte TSHRs are required for normal TSH-induced lipolysis (10-fold lower sensitivity in KO adipocytes) and normal adipocyte size regulation; catecholamine-induced lipolysis was unaffected, indicating TSH-specific signaling through adipocyte TSHR.","method":"Cre-loxP conditional knockout (Fabp4-Cre), isolated adipocyte lipolysis assays","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 2 — tissue-specific KO with specific functional readout (lipolysis assay), clean genetic model","pmids":["20152797"],"is_preprint":false},{"year":2010,"finding":"TSHR β-subunits (truncated ectodomain constructs) dimerize with full-length TSHR via direct protein-protein interaction, reducing cell-surface expression of full-length receptors and significantly decreasing TSH-induced cAMP generation without altering constitutive cAMP levels; faster internalization of β-subunits was identified as a contributing mechanism.","method":"Co-immunoprecipitation, FRET, transfection in HEK293 cells, cAMP assay, flow cytometry","journal":"Molecular endocrinology","confidence":"High","confidence_rationale":"Tier 1-2 — reciprocal co-IP confirmed by FRET, functional consequence measured by cAMP assay","pmids":["20719860"],"is_preprint":false},{"year":2012,"finding":"TSHR-stimulated cAMP production in orbital fibroblasts from Graves' ophthalmopathy patients is exclusively mediated via TSHR, as demonstrated by complete blockade of rhTSH-, GD-IgG-, and M22-induced cAMP production by the low-molecular-weight TSHR antagonist Org-274179-0 in dose-dependent fashion.","method":"cAMP assay, small molecule antagonist pharmacology in differentiated orbital fibroblast cultures","journal":"The Journal of clinical endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 — functional pharmacological dissection in primary human cells, single lab","pmids":["22419705"],"is_preprint":false},{"year":2007,"finding":"Posttranslational modifications of TSHR—including sialylation, phosphorylation, glycosylation, and oligomerization—influence TSHR cell-surface expression and signaling; increased sialylation results in increased TSHR cell-surface expression. TSHR also couples to the MAPK pathway through GRKs and arrestins in addition to Gαs and Gαq.","method":"Review synthesizing published biochemical studies on TSHR modifications","journal":"Trends in endocrinology and metabolism","confidence":"Low","confidence_rationale":"Tier 3 — review article summarizing findings, no new primary data","pmids":["17524661"],"is_preprint":false},{"year":2011,"finding":"Systematic mutagenesis of 41 residues in the TSHR hinge region identified new TSH contact points including a binding domain from position F381 to D386; negative charge, aromatic, and hydrophilic amino acid properties contribute to hormone-TSHR hinge interaction; same positions affect binding of superagonistic TSH analog TR1401.","method":"Site-directed mutagenesis, TSH binding assay, cell surface expression analysis","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 1 — systematic in vitro mutagenesis of 41 residues with binding and expression readouts","pmids":["21628383"],"is_preprint":false},{"year":2015,"finding":"TSH/TSHR signaling suppresses fatty acid synthase (FASN) expression in mature adipocytes via PKA activation, CREB phosphorylation, and ERK1/2 activation; PKA and ERK inhibitors partially abolished TSH-induced FASN downregulation, whereas JNK inhibition had no effect.","method":"In vitro adipocyte culture, pharmacological inhibitors (PKA, ERK, JNK), Western blot, RT-PCR","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple pharmacological dissection experiments with defined pathway inhibitors, single lab","pmids":["25655684"],"is_preprint":false},{"year":2022,"finding":"TSH activates TSHR to induce tumor PD-L1 expression through the TSHR-AC-PKA-JNK-c-JUN signaling pathway in thyroid cancer and glioma cells; moDCs in the tumor microenvironment are a primary source of TSH; TSHR inhibition reversed tumor immune evasion by reducing PD-L1 expression.","method":"Single-cell transcriptomics, transcriptomic sequencing, Western blotting, luciferase reporter, in vivo homograft mouse models, TSHR inhibitor treatment","journal":"Journal for immunotherapy of cancer","confidence":"Medium","confidence_rationale":"Tier 2 — multiple methods including in vivo models and mechanistic pathway dissection, single lab","pmids":["35101946"],"is_preprint":false},{"year":2024,"finding":"TSH/TSHR signaling in CD8+ tumor-infiltrating lymphocytes promotes T cell exhaustion through the PKA/CREB signaling pathway, upregulating PD-1 and TIM3; conditional TSHR deletion in CD8+ TILs improved effector differentiation. CRC cells secreted TSHR via exosomes to increase TSHR levels in CD8+ T cells, and MDSCs were identified as the main source of TSH in the tumor microenvironment.","method":"Conditional TSHR knockout, RNA-sequencing, Western blotting, ChIP, luciferase assay, immunofluorescence, flow cytometry","journal":"Cancer communications","confidence":"High","confidence_rationale":"Tier 1-2 — conditional KO with mechanistic pathway characterization using multiple orthogonal methods","pmids":["39285586"],"is_preprint":false},{"year":2000,"finding":"A novel germline TSHR mutation (Met463Val) in the second membrane-spanning domain causes constitutive activation of the cAMP pathway, producing hereditary non-autoimmune hyperthyroidism; functional studies confirmed ligand-independent cAMP production.","method":"Sanger sequencing, functional cAMP assay in transfected cells","journal":"Thyroid","confidence":"Medium","confidence_rationale":"Tier 2 — functional in vitro characterization of mutation confirming constitutive cAMP activation","pmids":["11201847"],"is_preprint":false},{"year":2011,"finding":"TSHR intron 1 SNP rs179247 predisposing allele is associated with significantly lower TSHR mRNA expression in thymus; allele-specific transcript quantification in heterozygotes confirmed that the predisposing allele is expressed at lower level than the protective allele in both thymic epithelial cells and thymocytes, linking impaired central tolerance to Graves' disease susceptibility.","method":"Quantitative PCR, allele-specific transcript quantification in thymic tissue","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 — direct measurement of allele-specific expression in human tissues, single lab","pmids":["21642385"],"is_preprint":false},{"year":2015,"finding":"TSHR is expressed and functional in thymocytes; Graves' disease stimulating autoantibodies (TSAbs) can stimulate thymocytes through TSHR, as demonstrated by functional signaling assays; TSHR expression is confined to maturing thymocytes.","method":"Protein immunoblotting, quantitative PCR, functional signaling assays","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — direct functional demonstration using antibody stimulation with protein-level confirmation","pmids":["25801430"],"is_preprint":false},{"year":2011,"finding":"Inactivating TSHR mutations can selectively abrogate Gq-coupled signaling while partially retaining Gs-coupled signaling (as shown for R450H); this differential coupling defect (Gq-dominant) correlates with a paradoxical non-classic phenotype of high radioiodine uptake in TSH resistance patients.","method":"In vitro expression of mutant TSHRs with cAMP assay (Gs) and alternative pathway assays (Gq) in transfected cells","journal":"The Journal of clinical endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 — functional characterization of dual signaling pathways with patient genotype-phenotype correlation","pmids":["21677043"],"is_preprint":false},{"year":2021,"finding":"TSH/TSHR signaling in Schwann cells (RSC96) induces oxidative stress, mitochondrial dysfunction, and apoptosis; TSHR knockout or inhibition of TSHR palmitoylation alleviated TSH-induced apoptosis, identifying palmitoylation as a post-translational modification regulating TSHR function in Schwann cells.","method":"TSHR knockout, inhibition of palmitoylation, oxidative stress assays, apoptosis assay, in vivo mouse model","journal":"Oxidative medicine and cellular longevity","confidence":"Medium","confidence_rationale":"Tier 2 — TSHR KO with specific cellular phenotype and novel PTM (palmitoylation) finding","pmids":["34804362"],"is_preprint":false},{"year":2016,"finding":"Thyrostimulin-TSHR signaling promotes ovarian cancer cell proliferation via PKA-independent trans-activation of EGFR, requiring MEK-ERK and PI3K-AKT cascades; pharmacological dissection with multiple inhibitors confirmed pathway requirements.","method":"Cell proliferation assays, pharmacological inhibitors (PKA, MEK, PI3K, EGFR), signaling assays in NIH:OVCAR-3 cells","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 — multiple inhibitor dissection experiments with defined pathway readouts, single lab","pmids":["27273257"],"is_preprint":false},{"year":2012,"finding":"PDGF-AB and PDGF-BB (but not PDGF-AA) increase TSHR expression on orbital fibroblasts; upregulated TSHR expression amplifies cAMP-mediated inflammatory cytokine (IL-6, IL-8, CCL2) and hyaluronan production in response to TSH and Graves' disease IgGs; TSHR blocking antibody K1-70 and cAMP inhibitor H89 confirmed TSHR/cAMP dependence.","method":"Flow cytometry, ELISA, TSHR blocking antibody and cAMP inhibitor pharmacology in primary orbital fibroblasts","journal":"The Journal of clinical endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 — receptor expression quantified and functional downstream signaling confirmed with blocking antibody and inhibitor controls","pmids":["22438231"],"is_preprint":false},{"year":2021,"finding":"In thyroid cancer cells undergoing dedifferentiation, TSH/TSHR preferentially couples to Gα12/13 (rather than canonical Gαs), activating RhoA via LARG (leukemia-associated RhoA GEF), promoting a pro-migratory phenotype; PI3K/AKT/mTOR signaling enhances Gα12/13 signaling by increasing LARG levels while inhibiting Gαs signaling and thyroid-specific gene expression.","method":"Signaling pathway analysis, Western blotting, LARG expression studies in thyroid cancer cell lines","journal":"Frontiers in oncology","confidence":"Medium","confidence_rationale":"Tier 2 — identification of non-canonical G-protein coupling with mechanistic crosstalk characterization","pmids":["34650915"],"is_preprint":false},{"year":2018,"finding":"Liver-specific conditional knockout of TSHR reduced hepatic triglyceride and cholesterol contents by modifying synthesis and catabolism of lipids and decreased serum LDL-C, while systemic energy metabolism was unaffected, demonstrating a direct role for hepatic TSHR in liver lipid metabolism.","method":"Cre/LoxP conditional liver-specific knockout, lipid measurements, metabolic chamber analysis","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 2 — tissue-specific KO with defined metabolic phenotype, clean genetic model","pmids":["29421660"],"is_preprint":false},{"year":2008,"finding":"Novel TSHR mutations (P27T, E34K, R46P, D403N, W488R, M527T) identified in congenital hypothyroidism patients were functionally characterized: R46P and W488R completely abolished TSH binding and cAMP response; E34K, D403N, and M527T showed reduced cAMP response and TSH binding capacity, confirming their loss-of-function nature.","method":"Site-directed mutagenesis, cAMP assay, 125I-TSH binding assay, microchip flow cytometry in COS cells","journal":"Clinical endocrinology","confidence":"High","confidence_rationale":"Tier 1 — in vitro functional characterization with binding and signaling assays plus surface expression","pmids":["18727713"],"is_preprint":false},{"year":2023,"finding":"PFOA reduces TSHR mRNA expression and impairs TSHR N-glycosylation in thyroid follicular cells, disrupting TSH-activated cAMP/CREB signaling and downstream transcription of thyroid-specific genes (NIS, TG, TPO); forskolin treatment (bypassing TSHR) rescued CREB phosphorylation, confirming TSHR as the disruption target.","method":"qPCR, Western blot, cAMP assay, CREB phosphorylation, glycosylation analysis, forskolin rescue experiment in FRTL-5 cells","journal":"Environmental research","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic rescue experiment confirming TSHR as site of PFOA action, multiple assays","pmids":["37827365"],"is_preprint":false},{"year":2012,"finding":"TSHR knockdown in 3T3-L1 preadipocytes blocked adipocyte differentiation as assessed by Oil-Red-O staining and reduced expression of PPARγ and ALBP; TSHR expression was upregulated during adipogenesis, establishing a required role for TSHR in adipocyte differentiation.","method":"siRNA knockdown, Oil-Red-O staining, RT-PCR in 3T3-L1 cells","journal":"Lipids in health and disease","confidence":"Medium","confidence_rationale":"Tier 2 — loss-of-function with specific differentiation phenotype and molecular markers","pmids":["22289392"],"is_preprint":false},{"year":1998,"finding":"The N-terminal segment of the TSHR extracellular domain (residues 9-165, particularly 90-165) is required not only as a functional epitope for Graves' TSHRAbs but also for induction of TSHRAbs in an animal model; mice immunized with TSHR chimeras lacking this N-terminal region failed to develop TSHRAbs.","method":"TSHR/LH-CGR chimeric receptor immunization in AKR/N mice, TBII and TBAb functional assays","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 — systematic chimeric receptor approach in animal model with functional antibody assays","pmids":["9528975"],"is_preprint":false}],"current_model":"TSHR is a G protein-coupled receptor that primarily signals through Gαs to generate cAMP/PKA/CREB activation in thyroid follicular cells (controlling thyroid hormone synthesis, iodide transport, and proliferation via mTORC1), but also couples to Gαq, Gα12/13 (activating RhoA/LARG in cancer dedifferentiation), and non-canonical pathways (MAPK, PI3K/Akt, β-arrestin); its extracellular leucine-rich repeat domain binds TSH and autoantibodies at partially overlapping but distinct sites (as defined by crystal structures with M22 and K1-70); post-translational modifications including N-glycosylation and sialylation regulate surface expression, palmitoylation modulates signaling in Schwann cells, and β-subunit homo-dimerization after ectodomain cleavage dampens TSH-induced cAMP responses; beyond the thyroid, extrathyroidal TSHR in adipocytes regulates lipolysis and adipogenesis, in hepatocytes controls lipid metabolism, and in CD8+ T cells promotes exhaustion via PKA/CREB signaling."},"narrative":{"teleology":[{"year":1998,"claim":"Defining the autoantibody epitope on the TSHR ectodomain established that residues 90–165 of the N-terminal extracellular region are both necessary and sufficient for induction and recognition of Graves' disease TSH receptor autoantibodies, framing the structural basis of autoimmunity.","evidence":"TSHR/LH-CGR chimeric receptor immunization in mice with functional TBII and TBAb assays","pmids":["9528975"],"confidence":"Medium","gaps":["epitope mapping used chimeric receptors rather than atomic-resolution structures","did not resolve stimulating vs blocking antibody binding modes"]},{"year":2000,"claim":"Identification of a germline constitutively activating mutation (Met463Val) demonstrated that single residue changes in the transmembrane domain can lock TSHR in an active conformation, establishing the molecular basis of hereditary non-autoimmune hyperthyroidism.","evidence":"Sanger sequencing of patient DNA with functional cAMP assay in transfected cells","pmids":["11201847"],"confidence":"Medium","gaps":["structural mechanism of constitutive activation not resolved","limited to one mutation; spectrum of activating mutations not fully mapped at that time"]},{"year":2008,"claim":"Systematic functional characterization of six novel TSHR mutations in congenital hypothyroidism patients established genotype-function relationships, showing that mutations at different positions (extracellular vs transmembrane) differentially impair TSH binding and cAMP signaling.","evidence":"Site-directed mutagenesis with 125I-TSH binding, cAMP assay, and surface expression in COS cells","pmids":["18727713"],"confidence":"High","gaps":["Gq pathway not assessed for these mutations","no structural models to explain differential effects"]},{"year":2010,"claim":"Two key advances resolved TSHR regulation and extrathyroidal function: adipocyte-specific TSHR knockout proved a direct, non-thyroid role in lipolysis, while discovery that cleaved β-subunits dimerize with full-length TSHR and dampen TSH-induced cAMP revealed a novel negative-feedback mechanism at the receptor level.","evidence":"Cre-loxP adipocyte-specific KO with lipolysis assays; co-IP, FRET, and cAMP assays in HEK293 cells","pmids":["20152797","20719860"],"confidence":"High","gaps":["in vivo relevance of β-subunit dimerization not demonstrated","adipocyte KO did not distinguish downstream Gs vs Gq contributions"]},{"year":2011,"claim":"A convergence of structural, mutagenesis, and genetic studies resolved how TSH and autoantibodies engage the ectodomain: the K1-70 crystal structure showed blocking antibodies bind ~155° rotated relative to stimulating antibody M22, hinge-region mutagenesis identified F381–D386 as a TSH contact domain, differential Gs/Gq coupling of inactivating mutations explained paradoxical clinical phenotypes, and reduced thymic TSHR expression from a risk allele linked impaired central tolerance to Graves' disease.","evidence":"X-ray crystallography at 1.9 Å; systematic mutagenesis of 41 hinge residues; dual Gs/Gq functional assays; allele-specific transcript quantification in human thymus","pmids":["21247981","21628383","21677043","21642385"],"confidence":"High","gaps":["full-length TSHR structure including transmembrane domain not resolved","mechanism by which antibody orientation determines stimulating vs blocking activity not fully explained"]},{"year":2012,"claim":"Functional studies in extrathyroidal cells established TSHR as a required driver of adipocyte differentiation and as the exclusive mediator of cAMP-dependent inflammatory cytokine production in Graves' orbital fibroblasts, broadening TSHR's disease-relevant roles beyond thyroid hormone synthesis.","evidence":"siRNA knockdown in 3T3-L1 with adipogenesis markers; TSHR antagonist Org-274179-0 dose-response in primary orbital fibroblasts; PDGF-induced TSHR upregulation with blocking antibody controls","pmids":["22289392","22419705","22438231"],"confidence":"Medium","gaps":["downstream signaling branch (Gs vs Gq vs β-arrestin) mediating adipogenesis not resolved","orbital fibroblast studies did not address IGF-1R cross-talk in detail"]},{"year":2015,"claim":"TSH/TSHR signaling was shown to regulate adipocyte lipid metabolism (suppressing FASN via PKA/CREB and ERK) and orbital fibroblast proliferation (via PI3K/Akt and miR-146a/miR-155), demonstrating pathway-specific downstream effects in different extrathyroidal cell types.","evidence":"Pharmacological inhibitors with Western blot and qPCR in adipocytes; siRNA, BrdU assay, and PI3K inhibitor in orbital fibroblasts","pmids":["25655684","31622470"],"confidence":"Medium","gaps":["miR-146a/155 regulation not shown to be direct","adipocyte FASN regulation studied in vitro only"]},{"year":2017,"claim":"Identification of GLIS3 as a required downstream effector of TSH/TSHR that activates mTORC1 and directly regulates iodide transporter genes (NIS, PDS) provided a transcriptional framework linking receptor activation to thyroid-specific gene expression and proliferation.","evidence":"ChIP-Seq, promoter analysis, and conditional knockout mouse model","pmids":["29083325"],"confidence":"High","gaps":["how GLIS3 integrates with cAMP/PKA vs Gq branches not fully delineated","relevance to human thyroid disease beyond mouse model not confirmed"]},{"year":2018,"claim":"Liver-specific TSHR knockout reduced hepatic triglyceride and cholesterol content without affecting systemic energy metabolism, establishing a direct hepatocyte-autonomous role for TSHR in lipid homeostasis distinct from thyroid hormone effects.","evidence":"Cre-loxP liver-specific knockout with lipid measurements and metabolic chamber analysis","pmids":["29421660"],"confidence":"High","gaps":["downstream signaling pathway in hepatocytes not dissected","human relevance of hepatic TSHR signaling not established"]},{"year":2021,"claim":"Two studies expanded non-canonical TSHR coupling: in dedifferentiating thyroid cancer, TSH/TSHR shifts from Gαs to Gα12/13-RhoA via LARG to promote migration, while in Schwann cells, palmitoylation of TSHR was identified as a post-translational modification required for TSH-induced oxidative stress and apoptosis.","evidence":"Signaling pathway analysis and LARG expression in thyroid cancer cell lines; TSHR KO and palmitoylation inhibition in RSC96 Schwann cells with in vivo mouse model","pmids":["34650915","34804362"],"confidence":"Medium","gaps":["G-protein switching mechanism in cancer not structurally resolved","palmitoylation site on TSHR not mapped","Schwann cell findings from single lab"]},{"year":2022,"claim":"TSH/TSHR signaling was linked to tumor immune evasion by demonstrating that TSHR activation induces PD-L1 expression through an AC-PKA-JNK-c-JUN cascade in thyroid cancer and glioma, with moDCs serving as a local TSH source in the tumor microenvironment.","evidence":"Single-cell transcriptomics, luciferase reporter, and in vivo homograft mouse models with TSHR inhibitor","pmids":["35101946"],"confidence":"Medium","gaps":["JNK involvement contrasts with other studies showing JNK-independence in adipocytes; cell-type specificity unresolved","single-lab finding not independently replicated"]},{"year":2024,"claim":"Conditional TSHR deletion in CD8+ TILs proved that tumor-microenvironment TSH/TSHR signaling directly drives T cell exhaustion through PKA/CREB-dependent upregulation of PD-1 and TIM3, while CRC-derived exosomal TSHR transfer was identified as a mechanism increasing receptor levels on T cells.","evidence":"Conditional TSHR knockout in CD8+ T cells, RNA-seq, ChIP, luciferase assay, flow cytometry","pmids":["39285586"],"confidence":"High","gaps":["exosomal TSHR transfer mechanism not structurally characterized","whether TSHR-mediated exhaustion operates broadly across tumor types or is context-specific remains unknown"]},{"year":null,"claim":"A full-length TSHR structure including the transmembrane domain and G-protein coupling interfaces has not been solved, and the molecular determinants governing the switch from Gαs to Gα12/13 coupling during cancer dedifferentiation remain undefined.","evidence":"","pmids":[],"confidence":"Low","gaps":["no full-length TSHR cryo-EM or crystal structure available","mechanism of G-protein selectivity switch unresolved","in vivo validation of exosomal TSHR transfer in immunotherapy settings lacking"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,4,7,11,14,20]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[4,18]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,4,6,7,20,21]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,8,9,10,14,16,18]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[9,10,12,13]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[3,8,19]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[9,10,11,16,20]}],"complexes":[],"partners":["GLIS3","LARG","GNAS","GNA12","GNA13","GNAQ"],"other_free_text":[]},"mechanistic_narrative":"TSHR is a G protein-coupled receptor that transduces TSH signaling through multiple heterotrimeric G proteins—primarily Gαs/cAMP/PKA/CREB, but also Gαq and Gα12/13—to control thyroid hormone biosynthesis, iodide transport, and follicular cell proliferation, with the transcription factor GLIS3 acting as a critical downstream mediator linking TSH/TSHR to mTORC1 activation and thyroid-specific gene expression [PMID:29083325, PMID:21677043, PMID:34650915]. The extracellular leucine-rich repeat domain binds TSH through contacts on its concave surface and hinge region, and stimulating versus blocking autoantibodies engage this surface in nearly opposite orientations, as resolved by crystal structures with M22 and K1-70 [PMID:21247981, PMID:21628383]. Beyond the thyroid, tissue-specific knockouts demonstrate direct roles for TSHR in adipocyte lipolysis and differentiation, hepatic lipid metabolism, and—in the tumor microenvironment—promotion of CD8+ T cell exhaustion via PKA/CREB-dependent upregulation of PD-1 and TIM3 [PMID:20152797, PMID:29421660, PMID:39285586]. Germline gain-of-function mutations cause hereditary non-autoimmune hyperthyroidism, while loss-of-function mutations cause congenital hypothyroidism, and TSHR intron-1 variants that reduce thymic expression predispose to Graves' disease through impaired central tolerance [PMID:11201847, PMID:18727713, PMID:21642385]."},"prefetch_data":{"uniprot":{"accession":"P16473","full_name":"Thyrotropin receptor","aliases":["Thyroid-stimulating hormone receptor","TSH-R"],"length_aa":764,"mass_kda":86.8,"function":"Receptor for the thyroid-stimulating hormone (TSH) or thyrotropin (PubMed:11847099, PubMed:12045258). Also acts as a receptor for the heterodimeric glycoprotein hormone (GPHA2:GPHB5) or thyrostimulin (PubMed:12045258). TSHR is coupled to G(s) proteins and mediates the activation of adenylate cyclase (PubMed:11847099, PubMed:35940205, PubMed:35940204). This leads to the generation of cyclic adenosine monophosphate (cAMP), which in turn activates protein kinase A (PKA). PKA subsequently phosphorylates downstream targets involved in thyroid hormone biosynthesis and secretion, including thyroid peroxidase (TPO) and the sodium/iodide symporter (NIS) (PubMed:27638195). Additionally, plays a central role in controlling thyroid cell metabolism (By similarity)","subcellular_location":"Cell membrane; Basolateral cell membrane","url":"https://www.uniprot.org/uniprotkb/P16473/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TSHR","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TSHR","total_profiled":1310},"omim":[{"mim_id":"612842","title":"RASD FAMILY, MEMBER 2; RASD2","url":"https://www.omim.org/entry/612842"},{"mim_id":"609893","title":"HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 3; CHNG3","url":"https://www.omim.org/entry/609893"},{"mim_id":"609152","title":"HYPERTHYROIDISM, NONAUTOIMMUNE","url":"https://www.omim.org/entry/609152"},{"mim_id":"608173","title":"AUTOIMMUNE THYROID DISEASE, SUSCEPTIBILITY TO, 1","url":"https://www.omim.org/entry/608173"},{"mim_id":"607358","title":"AUTOIMMUNE REGULATOR; AIRE","url":"https://www.omim.org/entry/607358"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"thyroid gland","ntpm":257.0}],"url":"https://www.proteinatlas.org/search/TSHR"},"hgnc":{"alias_symbol":["LGR3"],"prev_symbol":[]},"alphafold":{"accession":"P16473","domains":[{"cath_id":"1.20.1070.10","chopping":"416-697","consensus_level":"medium","plddt":83.1086,"start":416,"end":697}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P16473","model_url":"https://alphafold.ebi.ac.uk/files/AF-P16473-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P16473-F1-predicted_aligned_error_v6.png","plddt_mean":74.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TSHR","jax_strain_url":"https://www.jax.org/strain/search?query=TSHR"},"sequence":{"accession":"P16473","fasta_url":"https://rest.uniprot.org/uniprotkb/P16473.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P16473/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P16473"}},"corpus_meta":[{"pmid":"12608932","id":"PMC_12608932","title":"TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves' ophthalmopathy patients.","date":"2003","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/12608932","citation_count":196,"is_preprint":false},{"pmid":"26441350","id":"PMC_26441350","title":"Drosophila Lgr3 Couples Organ Growth with Maturation and Ensures Developmental Stability.","date":"2015","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/26441350","citation_count":136,"is_preprint":false},{"pmid":"26429885","id":"PMC_26429885","title":"A brain circuit that synchronizes growth and maturation revealed through Dilp8 binding to Lgr3.","date":"2015","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/26429885","citation_count":136,"is_preprint":false},{"pmid":"16106256","id":"PMC_16106256","title":"Association of the TSHR gene with Graves' disease: the first disease specific locus.","date":"2005","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/16106256","citation_count":134,"is_preprint":false},{"pmid":"15115450","id":"PMC_15115450","title":"Dry eye syndrome in thyroid-associated ophthalmopathy: lacrimal expression of TSH receptor suggests involvement of TSHR-specific autoantibodies.","date":"2004","source":"Acta ophthalmologica Scandinavica","url":"https://pubmed.ncbi.nlm.nih.gov/15115450","citation_count":127,"is_preprint":false},{"pmid":"26510564","id":"PMC_26510564","title":"Dilp8 requires the neuronal relaxin receptor Lgr3 to couple growth to developmental timing.","date":"2015","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/26510564","citation_count":125,"is_preprint":false},{"pmid":"21247981","id":"PMC_21247981","title":"Crystal structure of the TSH receptor (TSHR) bound to a blocking-type TSHR autoantibody.","date":"2011","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21247981","citation_count":100,"is_preprint":false},{"pmid":"19244275","id":"PMC_19244275","title":"Association of the thyroid stimulating hormone receptor gene (TSHR) with Graves' disease.","date":"2009","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19244275","citation_count":100,"is_preprint":false},{"pmid":"17803697","id":"PMC_17803697","title":"Effects of serum TSH and FT4 levels and the TSHR-Asp727Glu polymorphism on bone: the Rotterdam Study.","date":"2007","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/17803697","citation_count":98,"is_preprint":false},{"pmid":"25303483","id":"PMC_25303483","title":"Genetic predisposition to papillary thyroid carcinoma: involvement of FOXE1, TSHR, and a novel lincRNA gene, PTCSC2.","date":"2015","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/25303483","citation_count":86,"is_preprint":false},{"pmid":"22289392","id":"PMC_22289392","title":"Role of extrathyroidal TSHR expression in adipocyte differentiation and its association with obesity.","date":"2012","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/22289392","citation_count":84,"is_preprint":false},{"pmid":"8501149","id":"PMC_8501149","title":"The thyrotropin receptor (TSH-R) is not an oncogene for thyroid tumors: structural studies of the TSH-R and the alpha-subunit of Gs in human thyroid neoplasms.","date":"1993","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/8501149","citation_count":76,"is_preprint":false},{"pmid":"28054989","id":"PMC_28054989","title":"Effects of Long-Term In Vivo Exposure to Di-2-Ethylhexylphthalate on Thyroid Hormones and the TSH/TSHR Signaling Pathways in Wistar Rats.","date":"2017","source":"International journal of environmental research and public health","url":"https://pubmed.ncbi.nlm.nih.gov/28054989","citation_count":70,"is_preprint":false},{"pmid":"27558136","id":"PMC_27558136","title":"Growth Coordination During Drosophila melanogaster Imaginal Disc Regeneration Is Mediated by Signaling Through the Relaxin Receptor Lgr3 in the Prothoracic Gland.","date":"2016","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27558136","citation_count":68,"is_preprint":false},{"pmid":"29083325","id":"PMC_29083325","title":"GLIS3 is indispensable for TSH/TSHR-dependent thyroid hormone biosynthesis and follicular cell proliferation.","date":"2017","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/29083325","citation_count":62,"is_preprint":false},{"pmid":"31622470","id":"PMC_31622470","title":"TSHR Signaling Stimulates Proliferation Through PI3K/Akt and Induction of miR-146a and miR-155 in Thyroid Eye Disease Orbital Fibroblasts.","date":"2019","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/31622470","citation_count":58,"is_preprint":false},{"pmid":"11502798","id":"PMC_11502798","title":"A comprehensive analysis of MNG1, TCO1, fPTC, PTEN, TSHR, and TRKA in familial nonmedullary thyroid cancer: confirmation of linkage to TCO1.","date":"2001","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/11502798","citation_count":58,"is_preprint":false},{"pmid":"33558728","id":"PMC_33558728","title":"Tumour-derived Dilp8/INSL3 induces cancer anorexia by regulating feeding neuropeptides via Lgr3/8 in the brain.","date":"2021","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/33558728","citation_count":57,"is_preprint":false},{"pmid":"20926595","id":"PMC_20926595","title":"Genetic hyperthyroidism: hyperthyroidism due to activating TSHR mutations.","date":"2010","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/20926595","citation_count":57,"is_preprint":false},{"pmid":"21642385","id":"PMC_21642385","title":"Association of an SNP with intrathymic transcription of TSHR and Graves' disease: a role for defective thymic tolerance.","date":"2011","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21642385","citation_count":56,"is_preprint":false},{"pmid":"19438904","id":"PMC_19438904","title":"Clinical associations of the genetic variants of CTLA-4, Tg, TSHR, PTPN22, PTPN12 and FCRL3 in patients with Graves' disease.","date":"2009","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/19438904","citation_count":55,"is_preprint":false},{"pmid":"20083159","id":"PMC_20083159","title":"Genetics of thyroid autoimmunity and the role of the TSHR.","date":"2010","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/20083159","citation_count":51,"is_preprint":false},{"pmid":"11201847","id":"PMC_11201847","title":"Novel TSHR germline mutation (Met463Val) masquerading as Graves' disease in a large Welsh kindred with hyperthyroidism.","date":"2000","source":"Thyroid : official journal of the American Thyroid Association","url":"https://pubmed.ncbi.nlm.nih.gov/11201847","citation_count":51,"is_preprint":false},{"pmid":"29715504","id":"PMC_29715504","title":"The biology and evolution of the Dilp8-Lgr3 pathway: A relaxin-like pathway coupling tissue growth and developmental timing control.","date":"2018","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/29715504","citation_count":50,"is_preprint":false},{"pmid":"35101946","id":"PMC_35101946","title":"TSH-TSHR axis promotes tumor immune evasion.","date":"2022","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35101946","citation_count":49,"is_preprint":false},{"pmid":"18694911","id":"PMC_18694911","title":"Prevalence of mutations in TSHR, GNAS, PRKAR1A and RAS genes in a large series of toxic thyroid adenomas from Galicia, an iodine-deficient area in NW Spain.","date":"2008","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/18694911","citation_count":46,"is_preprint":false},{"pmid":"20535589","id":"PMC_20535589","title":"Qualitative and quantitative promoter hypermethylation patterns of the P16, TSHR, RASSF1A and RARβ2 genes in papillary thyroid carcinoma.","date":"2010","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/20535589","citation_count":44,"is_preprint":false},{"pmid":"26361260","id":"PMC_26361260","title":"Mechanisms of Action of TSHR Autoantibodies.","date":"2015","source":"Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","url":"https://pubmed.ncbi.nlm.nih.gov/26361260","citation_count":41,"is_preprint":false},{"pmid":"20152797","id":"PMC_20152797","title":"Tissue-specific knockout of TSHr in white adipose tissue increases adipocyte size and decreases TSH-induced lipolysis.","date":"2010","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/20152797","citation_count":41,"is_preprint":false},{"pmid":"26884206","id":"PMC_26884206","title":"Sex-specific regulation of Lgr3 in Drosophila neurons.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/26884206","citation_count":40,"is_preprint":false},{"pmid":"8103771","id":"PMC_8103771","title":"Dual mechanism of perturbation of thyrotropin-mediated activation of thyroid cells by antibodies to the thyrotropin receptor (TSHR) and TSHR-derived peptides.","date":"1993","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/8103771","citation_count":40,"is_preprint":false},{"pmid":"36742308","id":"PMC_36742308","title":"A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves' orbitopathy.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36742308","citation_count":37,"is_preprint":false},{"pmid":"34751400","id":"PMC_34751400","title":"CAR-T Cells Targeting TSHR Demonstrate Safety and Potent Preclinical Activity Against Differentiated Thyroid Cancer.","date":"2022","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/34751400","citation_count":37,"is_preprint":false},{"pmid":"22438231","id":"PMC_22438231","title":"PDGF enhances orbital fibroblast responses to TSHR stimulating autoantibodies in Graves' ophthalmopathy patients.","date":"2012","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/22438231","citation_count":36,"is_preprint":false},{"pmid":"22419705","id":"PMC_22419705","title":"Complete inhibition of rhTSH-, Graves' disease IgG-, and M22-induced cAMP production in differentiated orbital fibroblasts by a low-molecular-weight TSHR antagonist.","date":"2012","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/22419705","citation_count":34,"is_preprint":false},{"pmid":"17524661","id":"PMC_17524661","title":"Modulation of TSHR signaling by posttranslational modifications.","date":"2007","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/17524661","citation_count":33,"is_preprint":false},{"pmid":"21124799","id":"PMC_21124799","title":"Thyroid stimulating hormone receptor (TSHR) intron 1 variants are major risk factors for Graves' disease in three European Caucasian cohorts.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21124799","citation_count":33,"is_preprint":false},{"pmid":"22492869","id":"PMC_22492869","title":"A TSHR-LH/CGR chimera that measures functional thyroid-stimulating autoantibodies (TSAb) can predict remission or recurrence in Graves' patients undergoing antithyroid drug (ATD) treatment.","date":"2012","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/22492869","citation_count":33,"is_preprint":false},{"pmid":"28127991","id":"PMC_28127991","title":"TSHR as a therapeutic target in Graves' disease.","date":"2017","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/28127991","citation_count":32,"is_preprint":false},{"pmid":"8135775","id":"PMC_8135775","title":"Induction of thyrotropin receptor (TSH-R) autoantibodies and thyroiditis in mice immunised with the recombinant TSH-R.","date":"1994","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/8135775","citation_count":32,"is_preprint":false},{"pmid":"26361261","id":"PMC_26361261","title":"Genetics of Graves' Disease: Special Focus on the Role of TSHR Gene.","date":"2015","source":"Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","url":"https://pubmed.ncbi.nlm.nih.gov/26361261","citation_count":31,"is_preprint":false},{"pmid":"24927793","id":"PMC_24927793","title":"Epigenetic silencing of TSHR gene in thyroid cancer patients in relation to their BRAF V600E mutation status.","date":"2014","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/24927793","citation_count":31,"is_preprint":false},{"pmid":"21707688","id":"PMC_21707688","title":"Molecular screening of the TSH receptor (TSHR) and thyroid peroxidase (TPO) genes in Korean patients with nonsyndromic congenital hypothyroidism.","date":"2011","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21707688","citation_count":30,"is_preprint":false},{"pmid":"39285586","id":"PMC_39285586","title":"Local TSH/TSHR signaling promotes CD8+ T cell exhaustion and immune evasion in colorectal carcinoma.","date":"2024","source":"Cancer communications (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/39285586","citation_count":28,"is_preprint":false},{"pmid":"9528975","id":"PMC_9528975","title":"The formation of thyrotropin receptor (TSHR) antibodies in a Graves' animal model requires the N-terminal segment of the TSHR extracellular domain.","date":"1998","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/9528975","citation_count":27,"is_preprint":false},{"pmid":"27637299","id":"PMC_27637299","title":"Next-generation sequencing analysis of TSHR in 384 Chinese subclinical congenital hypothyroidism (CH) and CH patients.","date":"2016","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27637299","citation_count":27,"is_preprint":false},{"pmid":"21677043","id":"PMC_21677043","title":"Nonclassic TSH resistance: TSHR mutation carriers with discrepantly high thyroidal iodine uptake.","date":"2011","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/21677043","citation_count":26,"is_preprint":false},{"pmid":"34804362","id":"PMC_34804362","title":"TSH Combined with TSHR Aggravates Diabetic Peripheral Neuropathy by Promoting Oxidative Stress and Apoptosis in Schwann Cells.","date":"2021","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/34804362","citation_count":26,"is_preprint":false},{"pmid":"21511239","id":"PMC_21511239","title":"Small molecule TSHR agonists and antagonists.","date":"2011","source":"Annales d'endocrinologie","url":"https://pubmed.ncbi.nlm.nih.gov/21511239","citation_count":24,"is_preprint":false},{"pmid":"25801430","id":"PMC_25801430","title":"Graves' disease TSHR-stimulating antibodies (TSAbs) induce the activation of immature thymocytes: a clue to the riddle of TSAbs generation?","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25801430","citation_count":24,"is_preprint":false},{"pmid":"8864826","id":"PMC_8864826","title":"Yersinia enterocolitica envelope proteins that are crossreactive with the thyrotropin receptor (TSHR) also have B-cell mitogenic activity.","date":"1996","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/8864826","citation_count":23,"is_preprint":false},{"pmid":"27273257","id":"PMC_27273257","title":"Thyrostimulin-TSHR signaling promotes the proliferation of NIH:OVCAR-3 ovarian cancer cells via trans-regulation of the EGFR pathway.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27273257","citation_count":23,"is_preprint":false},{"pmid":"11833606","id":"PMC_11833606","title":"Consequences of hypothyroidism on auditory system function in Tshr mutant (hyt) mice.","date":"2001","source":"Journal of the Association for Research in Otolaryngology : JARO","url":"https://pubmed.ncbi.nlm.nih.gov/11833606","citation_count":23,"is_preprint":false},{"pmid":"23386414","id":"PMC_23386414","title":"Examination of orbital tissues in murine models of Graves' disease reveals expression of UCP-1 and the TSHR in retrobulbar adipose tissues.","date":"2013","source":"Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","url":"https://pubmed.ncbi.nlm.nih.gov/23386414","citation_count":22,"is_preprint":false},{"pmid":"31356790","id":"PMC_31356790","title":"Mutation screening of the TSHR gene in 220 Chinese patients with congenital hypothyroidism.","date":"2019","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31356790","citation_count":21,"is_preprint":false},{"pmid":"25655684","id":"PMC_25655684","title":"TSH/TSHR Signaling Suppresses Fatty Acid Synthase (FASN) Expression in Adipocytes.","date":"2015","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/25655684","citation_count":21,"is_preprint":false},{"pmid":"28455095","id":"PMC_28455095","title":"Next-generation sequencing of NKX2.1, FOXE1, PAX8, NKX2.5, and TSHR in 100 Chinese patients with congenital hypothyroidism and athyreosis.","date":"2017","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28455095","citation_count":21,"is_preprint":false},{"pmid":"29973096","id":"PMC_29973096","title":"Analysis of chosen polymorphisms rs2476601 a/G - PTPN22, rs1990760 C/T - IFIH1, rs179247 a/G - TSHR in pathogenesis of autoimmune thyroid diseases in children.","date":"2018","source":"Autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/29973096","citation_count":21,"is_preprint":false},{"pmid":"22985488","id":"PMC_22985488","title":"Follicular variant of papillary thyroid carcinoma presenting as toxic nodule in an adolescent: coexistent polymorphism of the TSHR and Gsα genes.","date":"2013","source":"Thyroid : official journal of the American Thyroid Association","url":"https://pubmed.ncbi.nlm.nih.gov/22985488","citation_count":21,"is_preprint":false},{"pmid":"22334716","id":"PMC_22334716","title":"Adoptive transfer of antithyrotropin receptor (TSHR) autoimmunity from TSHR knockout mice to athymic nude mice.","date":"2012","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/22334716","citation_count":20,"is_preprint":false},{"pmid":"29092890","id":"PMC_29092890","title":"Association between monoallelic TSHR mutations and congenital hypothyroidism: a statistical approach.","date":"2017","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/29092890","citation_count":20,"is_preprint":false},{"pmid":"28319174","id":"PMC_28319174","title":"Simultaneous induction of Graves' hyperthyroidism and Graves' ophthalmopathy by TSHR genetic immunization in BALB/c mice.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28319174","citation_count":20,"is_preprint":false},{"pmid":"37827365","id":"PMC_37827365","title":"Perfluorooctanoic acid disrupts thyroid-specific genes expression and regulation via the TSH-TSHR signaling pathway in thyroid cells.","date":"2023","source":"Environmental research","url":"https://pubmed.ncbi.nlm.nih.gov/37827365","citation_count":20,"is_preprint":false},{"pmid":"18727713","id":"PMC_18727713","title":"Functional studies of new TSH receptor (TSHr) mutations identified in patients affected by hypothyroidism or isolated hyperthyrotrophinaemia.","date":"2008","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/18727713","citation_count":19,"is_preprint":false},{"pmid":"25061884","id":"PMC_25061884","title":"Association between polymorphisms in the TSHR gene and Graves' orbitopathy.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25061884","citation_count":18,"is_preprint":false},{"pmid":"29344196","id":"PMC_29344196","title":"Downregulated expression of TSHR is associated with distant metastasis in thyroid cancer.","date":"2017","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/29344196","citation_count":17,"is_preprint":false},{"pmid":"29421660","id":"PMC_29421660","title":"Liver-specific deletion of TSHR inhibits hepatic lipid accumulation in mice.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/29421660","citation_count":17,"is_preprint":false},{"pmid":"31379878","id":"PMC_31379878","title":"Regulation of TSHR Expression in the Thyroid and Thymus May Contribute to TSHR Tolerance Failure in Graves' Disease Patients via Two Distinct Mechanisms.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31379878","citation_count":17,"is_preprint":false},{"pmid":"31966836","id":"PMC_31966836","title":"Luteolin suppresses tumor progression through lncRNA BANCR and its downstream TSHR/CCND1 signaling in thyroid carcinoma.","date":"2017","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31966836","citation_count":17,"is_preprint":false},{"pmid":"26519197","id":"PMC_26519197","title":"Methylation status of TSHr in well-differentiated thyroid cancer by using cytologic material.","date":"2015","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26519197","citation_count":16,"is_preprint":false},{"pmid":"32300552","id":"PMC_32300552","title":"Nevirapine Increases Sodium/Iodide Symporter-Mediated Radioiodide Uptake by Activation of TSHR/cAMP/CREB/PAX8 Signaling Pathway in Dedifferentiated Thyroid Cancer.","date":"2020","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32300552","citation_count":16,"is_preprint":false},{"pmid":"20719860","id":"PMC_20719860","title":"Subunit interactions influence TSHR multimerization.","date":"2010","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/20719860","citation_count":15,"is_preprint":false},{"pmid":"37690235","id":"PMC_37690235","title":"TSHR-based chimeric antigen receptor T cell specifically deplete auto-reactive B lymphocytes for treatment of autoimmune thyroid disease.","date":"2023","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37690235","citation_count":15,"is_preprint":false},{"pmid":"27762730","id":"PMC_27762730","title":"TSHR Gene Polymorphisms in the Enhancer Regions Are Most Strongly Associated with the Development of Graves' Disease, Especially Intractable Disease, and of Hashimoto's Disease.","date":"2016","source":"Thyroid : official journal of the American Thyroid Association","url":"https://pubmed.ncbi.nlm.nih.gov/27762730","citation_count":15,"is_preprint":false},{"pmid":"30655754","id":"PMC_30655754","title":"Association of BRAF gene and TSHR with cervical lymph node metastasis of papillary thyroid microcarcinoma.","date":"2018","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/30655754","citation_count":14,"is_preprint":false},{"pmid":"26260781","id":"PMC_26260781","title":"Mutations of TSHR and TP53 Genes in an Aggressive Clear Cell Follicular Carcinoma of the Thyroid.","date":"2015","source":"Endocrine pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26260781","citation_count":14,"is_preprint":false},{"pmid":"17608818","id":"PMC_17608818","title":"Preliminary evidence for interaction of PTPN12 polymorphism with TSHR genotype and association with Graves' ophthalmopathy.","date":"2007","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/17608818","citation_count":14,"is_preprint":false},{"pmid":"18306976","id":"PMC_18306976","title":"A novel TSHR gene mutation (Ile691Phe) in a Chinese family causing autosomal dominant non-autoimmune hyperthyroidism.","date":"2008","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18306976","citation_count":13,"is_preprint":false},{"pmid":"29973617","id":"PMC_29973617","title":"Concurrent TSHR mutations and DIO2 T92A polymorphism result in abnormal thyroid hormone metabolism.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29973617","citation_count":13,"is_preprint":false},{"pmid":"32279226","id":"PMC_32279226","title":"Association between TSHR gene methylation and papillary thyroid cancer: a meta-analysis.","date":"2020","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/32279226","citation_count":12,"is_preprint":false},{"pmid":"37919223","id":"PMC_37919223","title":"Thyroid-stimulating hormone receptor (TSHR) as a target for imaging differentiated thyroid cancer.","date":"2023","source":"Surgery","url":"https://pubmed.ncbi.nlm.nih.gov/37919223","citation_count":12,"is_preprint":false},{"pmid":"36142613","id":"PMC_36142613","title":"Sinomenine Hydrochloride Promotes TSHR-Dependent Redifferentiation in Papillary Thyroid Cancer.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36142613","citation_count":12,"is_preprint":false},{"pmid":"34650915","id":"PMC_34650915","title":"Crosstalk Between Abnormal TSHR Signaling Activation and PTEN/PI3K in the Dedifferentiation of Thyroid Cancer Cells.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34650915","citation_count":12,"is_preprint":false},{"pmid":"34751390","id":"PMC_34751390","title":"Capsaicin restores sodium iodine symporter-mediated radioiodine uptake through bypassing canonical TSH‒TSHR pathway in anaplastic thyroid carcinoma cells.","date":"2022","source":"Journal of molecular cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/34751390","citation_count":12,"is_preprint":false},{"pmid":"24690939","id":"PMC_24690939","title":"A deletion including exon 2 of the TSHR gene is associated with thyroid dysgenesis and severe congenital hypothyroidism.","date":"2014","source":"Journal of pediatric endocrinology & metabolism : JPEM","url":"https://pubmed.ncbi.nlm.nih.gov/24690939","citation_count":12,"is_preprint":false},{"pmid":"8981017","id":"PMC_8981017","title":"The gene for the thyrotropin receptor (TSHR) as a candidate gene for congenital hypothyroidism with thyroid dysgenesis.","date":"1996","source":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","url":"https://pubmed.ncbi.nlm.nih.gov/8981017","citation_count":12,"is_preprint":false},{"pmid":"32562184","id":"PMC_32562184","title":"Clinical diagnostic performance of a fully automated TSI immunoassay vs. that of an automated anti‑TSHR immunoassay for Graves' disease: a Chinese multicenter study.","date":"2020","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/32562184","citation_count":11,"is_preprint":false},{"pmid":"20515734","id":"PMC_20515734","title":"Genetic defects, thyroid growth and malfunctions of the TSHR in pediatric patients.","date":"2010","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/20515734","citation_count":11,"is_preprint":false},{"pmid":"24845969","id":"PMC_24845969","title":"Controversial constitutive TSHR activity: patients, physiology, and in vitro characterization.","date":"2014","source":"Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","url":"https://pubmed.ncbi.nlm.nih.gov/24845969","citation_count":11,"is_preprint":false},{"pmid":"34172814","id":"PMC_34172814","title":"Functional differences between TSHR alleles associate with variation in spawning season in Atlantic herring.","date":"2021","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/34172814","citation_count":11,"is_preprint":false},{"pmid":"27525008","id":"PMC_27525008","title":"Upregulation of TSHR, TTF-1, and PAX8 in Nodular Goiter Is Associated with Iodine Deficiency in the Follicular Lumen.","date":"2016","source":"International journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/27525008","citation_count":11,"is_preprint":false},{"pmid":"21050930","id":"PMC_21050930","title":"Current standards, variations, and pitfalls for the determination of constitutive TSHR activity in vitro.","date":"2010","source":"Methods in enzymology","url":"https://pubmed.ncbi.nlm.nih.gov/21050930","citation_count":11,"is_preprint":false},{"pmid":"23592747","id":"PMC_23592747","title":"Epitope recognition in HLA-DR3 transgenic mice immunized to TSH-R protein or peptides.","date":"2013","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/23592747","citation_count":10,"is_preprint":false},{"pmid":"30304112","id":"PMC_30304112","title":"Mutation screening in the genes PAX-8, NKX2-5, TSH-R, HES-1 in cohort of 63 Brazilian children with thyroid dysgenesis.","date":"2018","source":"Archives of endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/30304112","citation_count":10,"is_preprint":false},{"pmid":"38976794","id":"PMC_38976794","title":"PET Imaging of Differentiated Thyroid Cancer with TSHR-Targeted [89Zr]Zr-TR1402.","date":"2024","source":"Molecular pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/38976794","citation_count":9,"is_preprint":false},{"pmid":"22842620","id":"PMC_22842620","title":"A somatic TSHR mutation in a patient with lung adenocarcinoma with bronchioloalveolar carcinoma, coronary artery disease and severe chronic obstructive pulmonary disease.","date":"2012","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/22842620","citation_count":9,"is_preprint":false},{"pmid":"21628383","id":"PMC_21628383","title":"Identification of novel TSH interaction sites by systematic binding analysis of the TSHR hinge region.","date":"2011","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21628383","citation_count":9,"is_preprint":false},{"pmid":"33636837","id":"PMC_33636837","title":"Analytical and Clinical Validation of Two Commercially Available Immunoassays Used in the Detection of TSHR Antibodies.","date":"2017","source":"The journal of applied laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33636837","citation_count":9,"is_preprint":false},{"pmid":"9054617","id":"PMC_9054617","title":"Genetic alterations in N-bis(2-hydroxypropyl)nitrosamine-induced rat transplantable thyroid carcinoma lines: analysis of the TSH-R, G(alpha)s, ras and p53 genes.","date":"1997","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/9054617","citation_count":9,"is_preprint":false},{"pmid":"28195550","id":"PMC_28195550","title":"Novel germline mutation (Leu512Met) in the thyrotropin receptor gene (TSHR) leading to sporadic non-autoimmune hyperthyroidism.","date":"2017","source":"Journal of pediatric endocrinology & metabolism : JPEM","url":"https://pubmed.ncbi.nlm.nih.gov/28195550","citation_count":9,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54592,"output_tokens":5517,"usd":0.123266},"stage2":{"model":"claude-opus-4-6","input_tokens":9139,"output_tokens":3355,"usd":0.194355},"total_usd":0.317621,"stage1_batch_id":"msgbatch_01RPbVc9PDH9zQmYK5Hs6srm","stage2_batch_id":"msgbatch_01JVbVLzeKN2yVrsGp3zC8aM","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2011,\n      \"finding\": \"Crystal structure of TSHR extracellular domain (residues 22-260) bound to blocking-type human monoclonal autoantibody K1-70 solved at 1.9 Å resolution, revealing that K1-70 binds the concave surface of the leucine-rich repeat domain (LRD) in approximately the opposite orientation (~155° rotation) to stimulating autoantibody M22, and more N-terminally on the TSHR concave surface; mutagenesis of interface residues confirmed functional relevance of observed contacts.\",\n      \"method\": \"X-ray crystallography at 1.9 Å + site-directed mutagenesis\",\n      \"journal\": \"Journal of molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with mutagenesis validation, single rigorous paper with multiple orthogonal methods\",\n      \"pmids\": [\"21247981\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TSHR signaling stimulates proliferation of orbital fibroblasts in thyroid eye disease via the PI3K/Akt pathway and through induction of miR-146a and miR-155, which reduce expression of anti-proliferative targets ZNRF3 and PTEN; TSHR-specific siRNA knockdown abolished TSH-induced proliferation.\",\n      \"method\": \"siRNA knockdown, BrdU proliferation assay, Western blot, qPCR, PI3K inhibitor (LY294002)\",\n      \"journal\": \"Investigative ophthalmology & visual science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean KD with defined cellular phenotype and multiple pathway inhibitors, single lab\",\n      \"pmids\": [\"31622470\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GLIS3 transcription factor acts downstream of TSH/TSHR signaling and is required for TSH/TSHR-mediated thyroid follicular cell proliferation and thyroid hormone biosynthesis; GLIS3 deficiency blocks TSH-mediated activation of the mTORC1/RPS6 pathway and directly regulates iodide transporter genes NIS and PDS.\",\n      \"method\": \"ChIP-Seq, promoter analysis, conditional knockout mouse model, signaling pathway analysis\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including ChIP-Seq, mouse KO model with defined phenotype, and pathway dissection\",\n      \"pmids\": [\"29083325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Tissue-specific knockout of TSHR in white adipose tissue demonstrated that adipocyte TSHRs are required for normal TSH-induced lipolysis (10-fold lower sensitivity in KO adipocytes) and normal adipocyte size regulation; catecholamine-induced lipolysis was unaffected, indicating TSH-specific signaling through adipocyte TSHR.\",\n      \"method\": \"Cre-loxP conditional knockout (Fabp4-Cre), isolated adipocyte lipolysis assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — tissue-specific KO with specific functional readout (lipolysis assay), clean genetic model\",\n      \"pmids\": [\"20152797\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"TSHR β-subunits (truncated ectodomain constructs) dimerize with full-length TSHR via direct protein-protein interaction, reducing cell-surface expression of full-length receptors and significantly decreasing TSH-induced cAMP generation without altering constitutive cAMP levels; faster internalization of β-subunits was identified as a contributing mechanism.\",\n      \"method\": \"Co-immunoprecipitation, FRET, transfection in HEK293 cells, cAMP assay, flow cytometry\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reciprocal co-IP confirmed by FRET, functional consequence measured by cAMP assay\",\n      \"pmids\": [\"20719860\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"TSHR-stimulated cAMP production in orbital fibroblasts from Graves' ophthalmopathy patients is exclusively mediated via TSHR, as demonstrated by complete blockade of rhTSH-, GD-IgG-, and M22-induced cAMP production by the low-molecular-weight TSHR antagonist Org-274179-0 in dose-dependent fashion.\",\n      \"method\": \"cAMP assay, small molecule antagonist pharmacology in differentiated orbital fibroblast cultures\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional pharmacological dissection in primary human cells, single lab\",\n      \"pmids\": [\"22419705\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Posttranslational modifications of TSHR—including sialylation, phosphorylation, glycosylation, and oligomerization—influence TSHR cell-surface expression and signaling; increased sialylation results in increased TSHR cell-surface expression. TSHR also couples to the MAPK pathway through GRKs and arrestins in addition to Gαs and Gαq.\",\n      \"method\": \"Review synthesizing published biochemical studies on TSHR modifications\",\n      \"journal\": \"Trends in endocrinology and metabolism\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — review article summarizing findings, no new primary data\",\n      \"pmids\": [\"17524661\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Systematic mutagenesis of 41 residues in the TSHR hinge region identified new TSH contact points including a binding domain from position F381 to D386; negative charge, aromatic, and hydrophilic amino acid properties contribute to hormone-TSHR hinge interaction; same positions affect binding of superagonistic TSH analog TR1401.\",\n      \"method\": \"Site-directed mutagenesis, TSH binding assay, cell surface expression analysis\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic in vitro mutagenesis of 41 residues with binding and expression readouts\",\n      \"pmids\": [\"21628383\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TSH/TSHR signaling suppresses fatty acid synthase (FASN) expression in mature adipocytes via PKA activation, CREB phosphorylation, and ERK1/2 activation; PKA and ERK inhibitors partially abolished TSH-induced FASN downregulation, whereas JNK inhibition had no effect.\",\n      \"method\": \"In vitro adipocyte culture, pharmacological inhibitors (PKA, ERK, JNK), Western blot, RT-PCR\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple pharmacological dissection experiments with defined pathway inhibitors, single lab\",\n      \"pmids\": [\"25655684\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TSH activates TSHR to induce tumor PD-L1 expression through the TSHR-AC-PKA-JNK-c-JUN signaling pathway in thyroid cancer and glioma cells; moDCs in the tumor microenvironment are a primary source of TSH; TSHR inhibition reversed tumor immune evasion by reducing PD-L1 expression.\",\n      \"method\": \"Single-cell transcriptomics, transcriptomic sequencing, Western blotting, luciferase reporter, in vivo homograft mouse models, TSHR inhibitor treatment\",\n      \"journal\": \"Journal for immunotherapy of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple methods including in vivo models and mechanistic pathway dissection, single lab\",\n      \"pmids\": [\"35101946\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TSH/TSHR signaling in CD8+ tumor-infiltrating lymphocytes promotes T cell exhaustion through the PKA/CREB signaling pathway, upregulating PD-1 and TIM3; conditional TSHR deletion in CD8+ TILs improved effector differentiation. CRC cells secreted TSHR via exosomes to increase TSHR levels in CD8+ T cells, and MDSCs were identified as the main source of TSH in the tumor microenvironment.\",\n      \"method\": \"Conditional TSHR knockout, RNA-sequencing, Western blotting, ChIP, luciferase assay, immunofluorescence, flow cytometry\",\n      \"journal\": \"Cancer communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — conditional KO with mechanistic pathway characterization using multiple orthogonal methods\",\n      \"pmids\": [\"39285586\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"A novel germline TSHR mutation (Met463Val) in the second membrane-spanning domain causes constitutive activation of the cAMP pathway, producing hereditary non-autoimmune hyperthyroidism; functional studies confirmed ligand-independent cAMP production.\",\n      \"method\": \"Sanger sequencing, functional cAMP assay in transfected cells\",\n      \"journal\": \"Thyroid\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional in vitro characterization of mutation confirming constitutive cAMP activation\",\n      \"pmids\": [\"11201847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"TSHR intron 1 SNP rs179247 predisposing allele is associated with significantly lower TSHR mRNA expression in thymus; allele-specific transcript quantification in heterozygotes confirmed that the predisposing allele is expressed at lower level than the protective allele in both thymic epithelial cells and thymocytes, linking impaired central tolerance to Graves' disease susceptibility.\",\n      \"method\": \"Quantitative PCR, allele-specific transcript quantification in thymic tissue\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct measurement of allele-specific expression in human tissues, single lab\",\n      \"pmids\": [\"21642385\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TSHR is expressed and functional in thymocytes; Graves' disease stimulating autoantibodies (TSAbs) can stimulate thymocytes through TSHR, as demonstrated by functional signaling assays; TSHR expression is confined to maturing thymocytes.\",\n      \"method\": \"Protein immunoblotting, quantitative PCR, functional signaling assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct functional demonstration using antibody stimulation with protein-level confirmation\",\n      \"pmids\": [\"25801430\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Inactivating TSHR mutations can selectively abrogate Gq-coupled signaling while partially retaining Gs-coupled signaling (as shown for R450H); this differential coupling defect (Gq-dominant) correlates with a paradoxical non-classic phenotype of high radioiodine uptake in TSH resistance patients.\",\n      \"method\": \"In vitro expression of mutant TSHRs with cAMP assay (Gs) and alternative pathway assays (Gq) in transfected cells\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional characterization of dual signaling pathways with patient genotype-phenotype correlation\",\n      \"pmids\": [\"21677043\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TSH/TSHR signaling in Schwann cells (RSC96) induces oxidative stress, mitochondrial dysfunction, and apoptosis; TSHR knockout or inhibition of TSHR palmitoylation alleviated TSH-induced apoptosis, identifying palmitoylation as a post-translational modification regulating TSHR function in Schwann cells.\",\n      \"method\": \"TSHR knockout, inhibition of palmitoylation, oxidative stress assays, apoptosis assay, in vivo mouse model\",\n      \"journal\": \"Oxidative medicine and cellular longevity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — TSHR KO with specific cellular phenotype and novel PTM (palmitoylation) finding\",\n      \"pmids\": [\"34804362\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Thyrostimulin-TSHR signaling promotes ovarian cancer cell proliferation via PKA-independent trans-activation of EGFR, requiring MEK-ERK and PI3K-AKT cascades; pharmacological dissection with multiple inhibitors confirmed pathway requirements.\",\n      \"method\": \"Cell proliferation assays, pharmacological inhibitors (PKA, MEK, PI3K, EGFR), signaling assays in NIH:OVCAR-3 cells\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple inhibitor dissection experiments with defined pathway readouts, single lab\",\n      \"pmids\": [\"27273257\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"PDGF-AB and PDGF-BB (but not PDGF-AA) increase TSHR expression on orbital fibroblasts; upregulated TSHR expression amplifies cAMP-mediated inflammatory cytokine (IL-6, IL-8, CCL2) and hyaluronan production in response to TSH and Graves' disease IgGs; TSHR blocking antibody K1-70 and cAMP inhibitor H89 confirmed TSHR/cAMP dependence.\",\n      \"method\": \"Flow cytometry, ELISA, TSHR blocking antibody and cAMP inhibitor pharmacology in primary orbital fibroblasts\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — receptor expression quantified and functional downstream signaling confirmed with blocking antibody and inhibitor controls\",\n      \"pmids\": [\"22438231\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In thyroid cancer cells undergoing dedifferentiation, TSH/TSHR preferentially couples to Gα12/13 (rather than canonical Gαs), activating RhoA via LARG (leukemia-associated RhoA GEF), promoting a pro-migratory phenotype; PI3K/AKT/mTOR signaling enhances Gα12/13 signaling by increasing LARG levels while inhibiting Gαs signaling and thyroid-specific gene expression.\",\n      \"method\": \"Signaling pathway analysis, Western blotting, LARG expression studies in thyroid cancer cell lines\",\n      \"journal\": \"Frontiers in oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — identification of non-canonical G-protein coupling with mechanistic crosstalk characterization\",\n      \"pmids\": [\"34650915\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Liver-specific conditional knockout of TSHR reduced hepatic triglyceride and cholesterol contents by modifying synthesis and catabolism of lipids and decreased serum LDL-C, while systemic energy metabolism was unaffected, demonstrating a direct role for hepatic TSHR in liver lipid metabolism.\",\n      \"method\": \"Cre/LoxP conditional liver-specific knockout, lipid measurements, metabolic chamber analysis\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — tissue-specific KO with defined metabolic phenotype, clean genetic model\",\n      \"pmids\": [\"29421660\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Novel TSHR mutations (P27T, E34K, R46P, D403N, W488R, M527T) identified in congenital hypothyroidism patients were functionally characterized: R46P and W488R completely abolished TSH binding and cAMP response; E34K, D403N, and M527T showed reduced cAMP response and TSH binding capacity, confirming their loss-of-function nature.\",\n      \"method\": \"Site-directed mutagenesis, cAMP assay, 125I-TSH binding assay, microchip flow cytometry in COS cells\",\n      \"journal\": \"Clinical endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro functional characterization with binding and signaling assays plus surface expression\",\n      \"pmids\": [\"18727713\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PFOA reduces TSHR mRNA expression and impairs TSHR N-glycosylation in thyroid follicular cells, disrupting TSH-activated cAMP/CREB signaling and downstream transcription of thyroid-specific genes (NIS, TG, TPO); forskolin treatment (bypassing TSHR) rescued CREB phosphorylation, confirming TSHR as the disruption target.\",\n      \"method\": \"qPCR, Western blot, cAMP assay, CREB phosphorylation, glycosylation analysis, forskolin rescue experiment in FRTL-5 cells\",\n      \"journal\": \"Environmental research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic rescue experiment confirming TSHR as site of PFOA action, multiple assays\",\n      \"pmids\": [\"37827365\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"TSHR knockdown in 3T3-L1 preadipocytes blocked adipocyte differentiation as assessed by Oil-Red-O staining and reduced expression of PPARγ and ALBP; TSHR expression was upregulated during adipogenesis, establishing a required role for TSHR in adipocyte differentiation.\",\n      \"method\": \"siRNA knockdown, Oil-Red-O staining, RT-PCR in 3T3-L1 cells\",\n      \"journal\": \"Lipids in health and disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with specific differentiation phenotype and molecular markers\",\n      \"pmids\": [\"22289392\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The N-terminal segment of the TSHR extracellular domain (residues 9-165, particularly 90-165) is required not only as a functional epitope for Graves' TSHRAbs but also for induction of TSHRAbs in an animal model; mice immunized with TSHR chimeras lacking this N-terminal region failed to develop TSHRAbs.\",\n      \"method\": \"TSHR/LH-CGR chimeric receptor immunization in AKR/N mice, TBII and TBAb functional assays\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — systematic chimeric receptor approach in animal model with functional antibody assays\",\n      \"pmids\": [\"9528975\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TSHR is a G protein-coupled receptor that primarily signals through Gαs to generate cAMP/PKA/CREB activation in thyroid follicular cells (controlling thyroid hormone synthesis, iodide transport, and proliferation via mTORC1), but also couples to Gαq, Gα12/13 (activating RhoA/LARG in cancer dedifferentiation), and non-canonical pathways (MAPK, PI3K/Akt, β-arrestin); its extracellular leucine-rich repeat domain binds TSH and autoantibodies at partially overlapping but distinct sites (as defined by crystal structures with M22 and K1-70); post-translational modifications including N-glycosylation and sialylation regulate surface expression, palmitoylation modulates signaling in Schwann cells, and β-subunit homo-dimerization after ectodomain cleavage dampens TSH-induced cAMP responses; beyond the thyroid, extrathyroidal TSHR in adipocytes regulates lipolysis and adipogenesis, in hepatocytes controls lipid metabolism, and in CD8+ T cells promotes exhaustion via PKA/CREB signaling.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"TSHR is a G protein-coupled receptor that transduces TSH signaling through multiple heterotrimeric G proteins—primarily Gαs/cAMP/PKA/CREB, but also Gαq and Gα12/13—to control thyroid hormone biosynthesis, iodide transport, and follicular cell proliferation, with the transcription factor GLIS3 acting as a critical downstream mediator linking TSH/TSHR to mTORC1 activation and thyroid-specific gene expression [PMID:29083325, PMID:21677043, PMID:34650915]. The extracellular leucine-rich repeat domain binds TSH through contacts on its concave surface and hinge region, and stimulating versus blocking autoantibodies engage this surface in nearly opposite orientations, as resolved by crystal structures with M22 and K1-70 [PMID:21247981, PMID:21628383]. Beyond the thyroid, tissue-specific knockouts demonstrate direct roles for TSHR in adipocyte lipolysis and differentiation, hepatic lipid metabolism, and—in the tumor microenvironment—promotion of CD8+ T cell exhaustion via PKA/CREB-dependent upregulation of PD-1 and TIM3 [PMID:20152797, PMID:29421660, PMID:39285586]. Germline gain-of-function mutations cause hereditary non-autoimmune hyperthyroidism, while loss-of-function mutations cause congenital hypothyroidism, and TSHR intron-1 variants that reduce thymic expression predispose to Graves' disease through impaired central tolerance [PMID:11201847, PMID:18727713, PMID:21642385].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Defining the autoantibody epitope on the TSHR ectodomain established that residues 90–165 of the N-terminal extracellular region are both necessary and sufficient for induction and recognition of Graves' disease TSH receptor autoantibodies, framing the structural basis of autoimmunity.\",\n      \"evidence\": \"TSHR/LH-CGR chimeric receptor immunization in mice with functional TBII and TBAb assays\",\n      \"pmids\": [\"9528975\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"epitope mapping used chimeric receptors rather than atomic-resolution structures\", \"did not resolve stimulating vs blocking antibody binding modes\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identification of a germline constitutively activating mutation (Met463Val) demonstrated that single residue changes in the transmembrane domain can lock TSHR in an active conformation, establishing the molecular basis of hereditary non-autoimmune hyperthyroidism.\",\n      \"evidence\": \"Sanger sequencing of patient DNA with functional cAMP assay in transfected cells\",\n      \"pmids\": [\"11201847\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"structural mechanism of constitutive activation not resolved\", \"limited to one mutation; spectrum of activating mutations not fully mapped at that time\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Systematic functional characterization of six novel TSHR mutations in congenital hypothyroidism patients established genotype-function relationships, showing that mutations at different positions (extracellular vs transmembrane) differentially impair TSH binding and cAMP signaling.\",\n      \"evidence\": \"Site-directed mutagenesis with 125I-TSH binding, cAMP assay, and surface expression in COS cells\",\n      \"pmids\": [\"18727713\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Gq pathway not assessed for these mutations\", \"no structural models to explain differential effects\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Two key advances resolved TSHR regulation and extrathyroidal function: adipocyte-specific TSHR knockout proved a direct, non-thyroid role in lipolysis, while discovery that cleaved β-subunits dimerize with full-length TSHR and dampen TSH-induced cAMP revealed a novel negative-feedback mechanism at the receptor level.\",\n      \"evidence\": \"Cre-loxP adipocyte-specific KO with lipolysis assays; co-IP, FRET, and cAMP assays in HEK293 cells\",\n      \"pmids\": [\"20152797\", \"20719860\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"in vivo relevance of β-subunit dimerization not demonstrated\", \"adipocyte KO did not distinguish downstream Gs vs Gq contributions\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"A convergence of structural, mutagenesis, and genetic studies resolved how TSH and autoantibodies engage the ectodomain: the K1-70 crystal structure showed blocking antibodies bind ~155° rotated relative to stimulating antibody M22, hinge-region mutagenesis identified F381–D386 as a TSH contact domain, differential Gs/Gq coupling of inactivating mutations explained paradoxical clinical phenotypes, and reduced thymic TSHR expression from a risk allele linked impaired central tolerance to Graves' disease.\",\n      \"evidence\": \"X-ray crystallography at 1.9 Å; systematic mutagenesis of 41 hinge residues; dual Gs/Gq functional assays; allele-specific transcript quantification in human thymus\",\n      \"pmids\": [\"21247981\", \"21628383\", \"21677043\", \"21642385\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"full-length TSHR structure including transmembrane domain not resolved\", \"mechanism by which antibody orientation determines stimulating vs blocking activity not fully explained\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Functional studies in extrathyroidal cells established TSHR as a required driver of adipocyte differentiation and as the exclusive mediator of cAMP-dependent inflammatory cytokine production in Graves' orbital fibroblasts, broadening TSHR's disease-relevant roles beyond thyroid hormone synthesis.\",\n      \"evidence\": \"siRNA knockdown in 3T3-L1 with adipogenesis markers; TSHR antagonist Org-274179-0 dose-response in primary orbital fibroblasts; PDGF-induced TSHR upregulation with blocking antibody controls\",\n      \"pmids\": [\"22289392\", \"22419705\", \"22438231\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"downstream signaling branch (Gs vs Gq vs β-arrestin) mediating adipogenesis not resolved\", \"orbital fibroblast studies did not address IGF-1R cross-talk in detail\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"TSH/TSHR signaling was shown to regulate adipocyte lipid metabolism (suppressing FASN via PKA/CREB and ERK) and orbital fibroblast proliferation (via PI3K/Akt and miR-146a/miR-155), demonstrating pathway-specific downstream effects in different extrathyroidal cell types.\",\n      \"evidence\": \"Pharmacological inhibitors with Western blot and qPCR in adipocytes; siRNA, BrdU assay, and PI3K inhibitor in orbital fibroblasts\",\n      \"pmids\": [\"25655684\", \"31622470\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"miR-146a/155 regulation not shown to be direct\", \"adipocyte FASN regulation studied in vitro only\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identification of GLIS3 as a required downstream effector of TSH/TSHR that activates mTORC1 and directly regulates iodide transporter genes (NIS, PDS) provided a transcriptional framework linking receptor activation to thyroid-specific gene expression and proliferation.\",\n      \"evidence\": \"ChIP-Seq, promoter analysis, and conditional knockout mouse model\",\n      \"pmids\": [\"29083325\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"how GLIS3 integrates with cAMP/PKA vs Gq branches not fully delineated\", \"relevance to human thyroid disease beyond mouse model not confirmed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Liver-specific TSHR knockout reduced hepatic triglyceride and cholesterol content without affecting systemic energy metabolism, establishing a direct hepatocyte-autonomous role for TSHR in lipid homeostasis distinct from thyroid hormone effects.\",\n      \"evidence\": \"Cre-loxP liver-specific knockout with lipid measurements and metabolic chamber analysis\",\n      \"pmids\": [\"29421660\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"downstream signaling pathway in hepatocytes not dissected\", \"human relevance of hepatic TSHR signaling not established\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Two studies expanded non-canonical TSHR coupling: in dedifferentiating thyroid cancer, TSH/TSHR shifts from Gαs to Gα12/13-RhoA via LARG to promote migration, while in Schwann cells, palmitoylation of TSHR was identified as a post-translational modification required for TSH-induced oxidative stress and apoptosis.\",\n      \"evidence\": \"Signaling pathway analysis and LARG expression in thyroid cancer cell lines; TSHR KO and palmitoylation inhibition in RSC96 Schwann cells with in vivo mouse model\",\n      \"pmids\": [\"34650915\", \"34804362\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"G-protein switching mechanism in cancer not structurally resolved\", \"palmitoylation site on TSHR not mapped\", \"Schwann cell findings from single lab\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"TSH/TSHR signaling was linked to tumor immune evasion by demonstrating that TSHR activation induces PD-L1 expression through an AC-PKA-JNK-c-JUN cascade in thyroid cancer and glioma, with moDCs serving as a local TSH source in the tumor microenvironment.\",\n      \"evidence\": \"Single-cell transcriptomics, luciferase reporter, and in vivo homograft mouse models with TSHR inhibitor\",\n      \"pmids\": [\"35101946\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"JNK involvement contrasts with other studies showing JNK-independence in adipocytes; cell-type specificity unresolved\", \"single-lab finding not independently replicated\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Conditional TSHR deletion in CD8+ TILs proved that tumor-microenvironment TSH/TSHR signaling directly drives T cell exhaustion through PKA/CREB-dependent upregulation of PD-1 and TIM3, while CRC-derived exosomal TSHR transfer was identified as a mechanism increasing receptor levels on T cells.\",\n      \"evidence\": \"Conditional TSHR knockout in CD8+ T cells, RNA-seq, ChIP, luciferase assay, flow cytometry\",\n      \"pmids\": [\"39285586\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"exosomal TSHR transfer mechanism not structurally characterized\", \"whether TSHR-mediated exhaustion operates broadly across tumor types or is context-specific remains unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A full-length TSHR structure including the transmembrane domain and G-protein coupling interfaces has not been solved, and the molecular determinants governing the switch from Gαs to Gα12/13 coupling during cancer dedifferentiation remain undefined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"no full-length TSHR cryo-EM or crystal structure available\", \"mechanism of G-protein selectivity switch unresolved\", \"in vivo validation of exosomal TSHR transfer in immunotherapy settings lacking\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 4, 7, 11, 14, 20]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [4, 18]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 4, 6, 7, 20, 21]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 8, 9, 10, 14, 16, 18]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [9, 10, 12, 13]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [3, 8, 19]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [9, 10, 11, 16, 20]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"GLIS3\",\n      \"LARG\",\n      \"GNAS\",\n      \"GNA12\",\n      \"GNA13\",\n      \"GNAQ\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}